- Home
- SJW vs MIRM Comparison
SJW vs MIRM Comparison
Compare SJW & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJW
- MIRM
- Stock Information
- Founded
- SJW 1866
- MIRM 2018
- Country
- SJW United States
- MIRM United States
- Employees
- SJW N/A
- MIRM N/A
- Industry
- SJW Water Supply
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- SJW Utilities
- MIRM Health Care
- Exchange
- SJW Nasdaq
- MIRM Nasdaq
- Market Cap
- SJW 1.9B
- MIRM 1.9B
- IPO Year
- SJW N/A
- MIRM 2019
- Fundamental
- Price
- SJW $54.37
- MIRM $40.00
- Analyst Decision
- SJW Strong Buy
- MIRM Strong Buy
- Analyst Count
- SJW 3
- MIRM 11
- Target Price
- SJW $57.00
- MIRM $58.55
- AVG Volume (30 Days)
- SJW 305.2K
- MIRM 447.2K
- Earning Date
- SJW 04-28-2025
- MIRM 05-07-2025
- Dividend Yield
- SJW 3.10%
- MIRM N/A
- EPS Growth
- SJW 7.09
- MIRM N/A
- EPS
- SJW 2.87
- MIRM N/A
- Revenue
- SJW $748,439,000.00
- MIRM $336,888,000.00
- Revenue This Year
- SJW $2.55
- MIRM $29.51
- Revenue Next Year
- SJW $3.99
- MIRM $20.27
- P/E Ratio
- SJW $18.91
- MIRM N/A
- Revenue Growth
- SJW 11.65
- MIRM 80.76
- 52 Week Low
- SJW $44.91
- MIRM $23.14
- 52 Week High
- SJW $62.18
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- SJW 53.94
- MIRM 41.05
- Support Level
- SJW $53.79
- MIRM $38.22
- Resistance Level
- SJW $55.54
- MIRM $40.14
- Average True Range (ATR)
- SJW 1.86
- MIRM 2.24
- MACD
- SJW 0.15
- MIRM 0.07
- Stochastic Oscillator
- SJW 75.57
- MIRM 48.50
About SJW SJW Group (DE)
SJW Group is a U.S. water utility services holding company that provides, stores, purifies and distributes water. The company predominantly operates in various Californian municipalities and also has operations in other states. Its operating segments include Water Utility Services and Real Estate Services. The majority of the company's revenue is derived from its water utility services segment.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.